Clinical trial · Observational

Micrometastases in Axillary Lymph Nodes in Breast Cancer, Post-neoadjuvant Chemotherapy

NCT06149884CI-TRIAL-00071816completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This study aims to investigate the significance of minimal residual axillary disease following NAC, with a particular focus on micrometastases (ypNmi), in comparison to pathologic lymph node-negative (ypN0) or macrometastases (ypN+). The investigators will further explore the prognostic implications of SLNmi for the prediction of axillary LN status and survival outcomes.

Conditions

Conditions (2)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Micrometastases	—	UNRESOLVED	—
Neoadjuvant Chemotherapy	—	UNRESOLVED	—

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Sentinel lymph node biopsy, axillary lymph node dissection	Procedure	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Recurrence-free survival
timeFrame
the interval from breast cancer diagnosis to the initial recurrence or death upto 5 years
description
locoregional recurrence, distant metastasis, any cause of death

Eligibility

Eligibility (as posted)

Sex: Female
Minimum age: 18 Years
Maximum age: 80 Years

Show eligibility criteria text

Inclusion Criteria:

* Stage II or III primary breast cancer patients
* Patients who performed neoadjuvant chemotherpay
* Patients who underwent axillary lymph node dissection with or without sentinel lymph node biopsy

Exclusion Criteria:

* Patients who performed upfront surgery
* De novo stage IV patients

References

Publications (0)

Data not yet available

No reference posted for this study.